Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of $18.08 billion. The enterprise value is $14.13 billion.
| Market Cap | 18.08B |
| Enterprise Value | 14.13B |
Important Dates
The next estimated earnings date is Wednesday, May 8, 2024.
| Earnings Date | May 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 653.79 million shares outstanding.
| Shares Outstanding | 653.79M |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 7.23% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 30.29 and the forward PE ratio is 26.04. Genmab's PEG ratio is 1.27.
| PE Ratio | 30.29 |
| Forward PE | 26.04 |
| PS Ratio | 7.40 |
| Forward PS | 0.90 |
| PB Ratio | 3.98 |
| P/FCF Ratio | 17.95 |
| PEG Ratio | 1.27 |
Enterprise Valuation
| EV / Earnings | 21.91 |
| EV / Sales | 5.79 |
| EV / EBITDA | n/a |
| EV / EBIT | 13.95 |
| EV / FCF | 14.04 |
Financial Position
The company has a current ratio of 13.34, with a Debt / Equity ratio of 0.02.
| Current Ratio | 13.34 |
| Quick Ratio | 13.34 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.11 |
| Interest Coverage | 4.99 |
Financial Efficiency
Return on equity (ROE) is 14.70% and return on invested capital (ROIC) is 12.69%.
| Return on Equity (ROE) | 14.70% |
| Return on Assets (ROA) | 13.10% |
| Return on Capital (ROIC) | 12.69% |
| Revenue Per Employee | $1.11M |
| Profits Per Employee | $292,532 |
| Employee Count | 2,204 |
| Asset Turnover | 0.50 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Genmab has paid $184.56 million in taxes.
| Income Tax | 184.56M |
| Effective Tax Rate | 22.26% |
Stock Price Statistics
The stock price has decreased by -31.48% in the last 52 weeks. The beta is 0.78, so Genmab's price volatility has been lower than the market average.
| Beta (1Y) | 0.78 |
| 52-Week Price Change | -31.48% |
| 50-Day Moving Average | 29.37 |
| 200-Day Moving Average | 32.54 |
| Relative Strength Index (RSI) | 40.33 |
| Average Volume (30 Days) | 561,880 |
Short Selling Information
| Short Interest | 2.40M |
| Short Previous Month | 2.05M |
| Short % of Shares Out | 0.17% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.05 |
Income Statement
In the last 12 months, Genmab had revenue of $2.44 billion and earned $644.74 million in profits. Earnings per share was $0.95.
| Revenue | 2.44B |
| Gross Profit | 2.33B |
| Operating Income | 764.26M |
| Pretax Income | 809.64M |
| Net Income | 644.74M |
| EBITDA | n/a |
| EBIT | 1.01B |
| Earnings Per Share (EPS) | $0.95 |
Balance Sheet
The company has $4.04 billion in cash and $110.60 million in debt, giving a net cash position of $3.93 billion or $6.01 per share.
| Cash & Cash Equivalents | 4.04B |
| Total Debt | 110.60M |
| Net Cash | 3.93B |
| Net Cash Per Share | $6.01 |
| Equity / Book Value | 4.54B |
| Book Value Per Share | 6.94 |
| Working Capital | 4.40B |
Cash Flow
In the last 12 months, operating cash flow was $1.06 billion and capital expenditures -$54.01 million, giving a free cash flow of $1.01 billion.
| Operating Cash Flow | 1.06B |
| Capital Expenditures | -54.01M |
| Free Cash Flow | 1.01B |
| FCF Per Share | $1.52 |
Margins
Gross margin is 95.62%, with operating and profit margins of 31.31% and 26.42%.
| Gross Margin | 95.62% |
| Operating Margin | 31.31% |
| Pretax Margin | 33.17% |
| Profit Margin | 26.42% |
| EBITDA Margin | n/a |
| EBIT Margin | 41.50% |
| FCF Margin | 41.22% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.36% |
| Shareholder Yield | -0.36% |
| Earnings Yield | 3.57% |
| FCF Yield | 5.57% |
Analyst Forecast
The average price target for Genmab is $45.20, which is 63.35% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $45.20 |
| Price Target Difference | 63.35% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 18.14% |
| EPS Growth Forecast (5Y) | 77.88% |
Stock Splits
The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.
| Last Split Date | May 1, 2018 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
Genmab has an Altman Z-Score of 23.44 and a Piotroski F-Score of 6.
| Altman Z-Score | 23.44 |
| Piotroski F-Score | 6 |